Peptide Libraray

MAD1

General Information

DRACP ID DRACP01035

Peptide Name MAD1

Sequence KRWHWWRRHWVVW

Sequence Length 13

UniProt ID Not available

PubChem CID Not available

Origin Synthetic

Type Synthetic peptide

Classification

Active ACP

Activity Information

Cell Line	Disease	Cancer Classified	Activity	Assay	Testing Time	Literature
A549	Lung adenocarcinoma	Carcinoma	IC50=36.2 µM	MTT assay	48h	1
OVCAR-3	High grade ovarian serous adenocarcinoma	Carcinoma	IC50=14.2 µM	MTT assay	48h	1
NCI/ADR-RES	High grade ovarian serous adenocarcinoma	Carcinoma	IC50=85.6 µM	MTT assay	48h	1
T24	Bladder carcinoma	Carcinoma	IC50>100 µM	MTT assay	48h	1

Hemolytic Activity Not available

Normal (non-cancerous) Cytotoxicity HUVEC: IC50>100 μM; NL20: IC50=76.9 μM

Target Not available

Affinity Not available

Mechanism Not available

Nature Anticancer; Antitumor; Antimicrobial

Structure Information

PDB ID Not available

Predicted Structure DRACP01035

Helicity Not available

Linear/Cyclic Linear

Disulfide/Other Bond Not available

N-terminal Modification Free

C-terminal Modification Amidation

Other Modification None

Chiral L

Physicochemical Information

Formula C101H132N32O14

Absent amino acids ACDEFGILMNPQSTY

Common amino acids W

Mass 223258

Pl 12.81

Basic residues 6

Acidic residues 0

Hydrophobic residues 7

Net charge 6

Boman Index -3990

Hydrophobicity -153.08

Aliphatic Index 44.62

Half Life
Mammalian: 1.3 hour
Yeast: 3 min
E.coli: 2 min

Extinction Coefficient cystines 27500

Absorbance 280nm 2291.67

Polar residues 0

Amino acid distribution

Literature Information

Literature 1

Pubmed ID 33184577

Title Re-engineering Antimicrobial Peptides into Oncolytics Targeting Drug-Resistant Ovarian Cancers

Doi 10.1007/s12195-020-00626-z

Year 2020

Patent

Patent ID Not available

Patent Title Not available

Other Iinformation Not available

Other Published ID Not available